Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The AMALFI study has been designed to see if using a new home ECG monitor called a Zio Patch, will increase the number of people detected early with atrial fibrillation. This could bring down their risk of having a stroke. To do this we have recruited just over 5,000 people. Half these people wore the Zio Patch and half did not. The reason for this approach is because we need to compare different approaches to find out which one is best for patients. To compare the two groups in AMALFI, we will count how many people are diagnosed with atrial fibrillation two and a half years, and five years after entering the study. We will then analyse if there was any difference in the number of atrial fibrillation events between those who had a patch and those who did not.

To enable us to do this, we need to collect information (data) over the course of the study, which will come either from your GP or NHS Digital. This will be information that is collected as standard practice (known as routinely collected data), not specifically for AMALFI. The data will let us know if you have been diagnosed with any significant new medical condition, or prescribed medication, or if you pass away during the study. It will also include data about any hospital stays, or major events such as a heart attack or stroke.